OHCA Provider Letter 2020-03 Prior authorization of Lumoxiti– Effective Aug 1, 2020

As authorized by Oklahoma Administrative Code (OAC)  317:30-5-77.2, effective Aug 1, 2020, the Oklahoma Health Care Authority (OHCA) will be adding a prior authorization requirement for Lumoxiti® (moxetumomab pasudotox-tdfk).

Please view the Provider Letter in its entirety here: Provider Letter 2020-03.

Submit all comments by close of business, Aug 3, 2020, via the comment box below.

 




Comments

Order:


Name (optional)


Email (optional)


Comment


 



Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.